Lithuania With over 120,000 people whose lives are affected by the disease in Lithuania; diabetes stands as one of the country’s major health issues today. Furthermore, as Marijus Valatka, general manager for Lithuania, Latvia and Estonia of Novo Nordisk – the world leader in insulin and diabetes drugs – explains, “Lithuania…
Brazil When combining the sheer size of Brazil – the fifth largest country in the world – with its tropical climate, its largely perfectible infrastructure, and the soaring importance of temperature sensitive biologicals, one understands the urgent need to develop solutions guaranteeing appropriate transport conditions in Brazil. “We may be vaguely…
India For multinational companies, despite ‘pharmerging markets’ not holding the hype and allure they once did, India still stands as a land of opportunity for a variety of reasons. Novartis India country president Jawed Zia points out that “India, in terms of demographics, is the youngest nation in the world. The…
Poland Drago Vuina, corporate vice-president of Novo Nordisk Eastern Europe, highlights Poland as the most significant market in the region and the on-going commitment to make innovative treatment options available for patients. Furthermore, he discusses Novo Nordisk’s strong commitment to social responsibility in each country throughout the region and the need…
Lithuania Marijus Valatka, general manager Lithuania, Latvia and Estonia at Novo Nordisk, explains the current challenges and areas for improvement in diabetes treatment in Lithuania and stresses the company’s commitment to not only bring medicines to the market but also enhance the quality of treatment fort diabetes and other serious chronic…
Brazil Allan Finkel, recently voted Novo Nordisk’s best GM globally, speaks about the partnerships and projects that the Brazilian affiliate organizes with doctors and patient associations to increase diabetes awareness in the country as well as their newly launched obesity treatment Saxenda®, which has seen tremendous success in Brazil. You took…
Tunisia Jean-François Courtet, who has been leading the Tunisian affiliate of Novo Nordisk as general manager for three years, discusses the prevalence of diabetes and lack of awareness thereof in Tunisia, the company’s ambition to launch a series of new products to the market, and Novo Nordisk’s continuing dedication to the…
Canada Brian Hilberdink, President of Novo Nordisk Canada, highlights the key role that Canada plays as a pilot market for exporting best practices globally, the focus that Novo Nordisk is placing on the undertreated condition of obesity in Canada, and the challenges and opportunities of running an innovative pharma business in…
Tunisia Diabetes is an important problem in Tunisia, with prevalence is expected to increase over the coming years. Jean-Francois Courtet, general manager of Novo Nordisk in Tunisia, points out rgar “diabetes is the second largest cause of death in Tunisia”. Moez Lindhallah Mokadem, director of Pharmacie Centrale de Tunisie (PCT), adds…
Austria Mogens Guldberg, general manager of Novo Nordisk Austria, the Danish global powerhouse focused on innovative diabetic treatments, provides a unique insight into the obstacles associated with launching innovative products in Austria as well as the revolution required in Austria’s diabetic approach. He also highlights how specifically Novo Nordisk assists in…
Ukraine Alexander Boiko, general manager of Novo Nordisk Ukraine, provides insights into the recent progress and remaining room for improvement in Ukraine’s health capacity when it comes to preventing, diagnosing, and treating diabetes, as well as the company’s unique commitment to partner with the government at the moment an unprecedented set…
See our Cookie Privacy Policy Here